Researchers from Sinai Health and the University of Toronto have gleaned new insights into how thyroid cancer could be more effectively treated.
The study, which looked at thyroid tumor tissues and thyroid nodule biopsies from 620 patients at Mount Sinai Hospital from 2016 to 2022, examined whether differences in patients’ RAS genomic variants were reflected in the status of their tumors. It also investigated the presence of the variant BRAF V600E and TERT promoter variants in the patient’s samples.
Researchers ultimately concluded that differences in RAS in combination with BRAF V600E and TERT promoter variants could be used to arrive at more accurate cancer diagnoses in patients with indeterminate thyroid nodules.
Leave a reply